This report was first published by Endpoints News. To see the original version, click here
A patient in Pfizer’s trial of its hemophilia drug Hympavzi died from a thrombotic stroke, the drugmaker said Monday.
Pfizer said it had informed regulators and investigators of the death. In a statement emailed to Endpoints News, it said that it didn’t “anticipate any impact to safety” for patients given Hympavzi.
您已阅读12%（405字），剩余88%（2859字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。